Laurie E Cohen1. 1. Director of the Neuroendocrinology Program, Division of Endocrinology, Boston Children's Hospital, and Assistant Professor of Pediatrics, Harvard Medical School, Boston, Massachusetts.
Abstract
IMPORTANCE: Approximately 2% of children are defined as having short stature. Deciding when to pursue recombinant human growth hormone therapy to increase adult height is controversial. OBJECTIVE: To review the management of children with idiopathic short stature, including diagnostic evaluation and therapeutic options. EVIDENCE REVIEW: Systematic literature search of PubMed, Embase, and the Cochrane Library databases. For height outcome, articles were limited to studies reporting adult height and to systematic reviews. FINDINGS: Recombinant human growth hormone therapy of children with idiopathic short stature increases height in some children. The estimated mean gain in adult height is 5.2 cm (2 in). The cost-benefit ratio is controversial. Treatment with growth hormone appears safe in the short term, while data on long-term effects are limited because studies of long-term efficacy were not powered to determine safety. CONCLUSIONS AND RELEVANCE: Growth hormone treatment may be considered in some children with idiopathic short stature.
IMPORTANCE: Approximately 2% of children are defined as having short stature. Deciding when to pursue recombinant humangrowth hormone therapy to increase adult height is controversial. OBJECTIVE: To review the management of children with idiopathic short stature, including diagnostic evaluation and therapeutic options. EVIDENCE REVIEW: Systematic literature search of PubMed, Embase, and the Cochrane Library databases. For height outcome, articles were limited to studies reporting adult height and to systematic reviews. FINDINGS: Recombinant humangrowth hormone therapy of children with idiopathic short stature increases height in some children. The estimated mean gain in adult height is 5.2 cm (2 in). The cost-benefit ratio is controversial. Treatment with growth hormone appears safe in the short term, while data on long-term effects are limited because studies of long-term efficacy were not powered to determine safety. CONCLUSIONS AND RELEVANCE: Growth hormone treatment may be considered in some children with idiopathic short stature.
Authors: Diego Jaramillo; Phuong Duong; Jie C Nguyen; Sogol Mostoufi-Moab; Michael K Nguyen; Andrew Moreau; Christian A Barrera; Shijie Hong; José G Raya Journal: Radiology Date: 2022-03-22 Impact factor: 29.146
Authors: João Soares Felício; Luísa Corrêa Janaú; Marcelle Alves Moraes; Nathalie Abdallah Zahalan; Fabrício de Souza Resende; Manuela Nascimento de Lemos; Norberto Jorge Kzan de Souza Neto; Isabela Imbelloni Farias de Franco; Loyane Tamyres Costa Leitão; Lilian de Souza d'Albuquerque Silva; Maria Clara Neres Iunes de Oliveira; Angélica Leite de Alcântara; Ana Carolina Contente Braga de Souza; Wanderson Maia da Silva; Márcia Costa Dos Santos; Natércia Neves Marques de Queiroz; Lorena Vilhena de Moraes; Antônio Bentes de Figueiredo; Ana Luiza Prieto Farinassi; Luciana Marques da Costa Farias; Danielle Dias da Silva; Karem Miléo Felício; João Felício Abrahão Neto Journal: Front Endocrinol (Lausanne) Date: 2019-09-19 Impact factor: 5.555